All information on this website is intended strictly for educational and research purposes only.
The content on OpenPep — including peptide profiles, clinical trial summaries, dosing information, and reconstitution calculators — must not be used for:
OpenPep aggregates publicly available clinical trial data and research. We do not sell, distribute, or recommend any substances. All AI-generated summaries are interpretations of published research and may contain errors.
Spadin (PE-22-28)
For educational and research purposes only. Not medical advice.
PE-22-28 (Spadin) is an exciting preclinical antidepressant peptide targeting the TREK-1 channel. Animal studies show rapid onset (4 days vs 21 days for SSRIs) and neurogenesis promotion. No human clinical trials yet — very early research stage.
Best Time
Morning
Method
nasal
Frequency
Daily
Half-life
~4 hours
Cycle Length
4-8 weeks
Storage
Refrigerate at 2-8°C.
Published Dosing Ranges
Create an account to access peptide research data.
Contraindications
Create an account to access peptide research data.
Trial data for this peptide is being processed. Check back soon.
Mechanism of Action
Antagonist of the TREK-1 potassium channel, mimicking the mechanism of action of SSRIs but through a novel pathway. Increases serotonin availability and promotes neurogenesis.
Reported by the community. These may not be supported by clinical evidence and are not medical recommendations.